The long-term effect of specific type II 5α-reductase inhibition with finasteride on bone mineral density in men: Results of a 4-year placebo controlled trial

Alvin M. Matsumoto, Lisa Tenover, Michael McClung, David Mobley, Jack Geller, Michael Sullivan, John Grayhack, Hunter Wessells, Dov Kadmon, Malachi Flanagan, Gang K. Zhang, Joseph Schmidt, Alice M. Taylor, Michael Lee, Joanne Waldstreicher

Research output: Contribution to journalArticle

54 Scopus citations

Abstract

Purpose: We determine the effect of long-term suppression of dihydrotestosterone with finasteride, a specific type II 5α-reductase inhibitor, on bone mineral density. Materials and Methods: As part of a large (3,040 cases) 4-year, double-blind, placebo controlled trial designed to assess the long-term effects of finasteride in men with benign prostatic hyperplasia, 157 men 46 to 76 years old who were randomized to receive either 5 mg. finasteride or placebo underwent dual energy x-ray absorptiometry of the lumbar spine at baseline and at years 2, 3 and 4. Results: Of 117 patients who had a baseline measurement and at least 1 additional measurement during the study baseline mean plus or minus standard deviation bone mineral density values were 1.12 ± 0.17 gm./cm.2 in the finasteride group (63) and 1.10 ± 0.17 gm./cm.2 in the placebo group (54). After 4 years bone mineral density was not different between treatment groups (finasteride 1.14 ± 0.17 gm./cm.2 and placebo 1.13, ± 0.18 gm./cm.2). Similar results were obtained for the 33 finasteride and 25 placebo treated patients who completed the study with year 4 bone mineral density measurements. Conclusions: These data demonstrate that long-term inhibition of type II 5α-reductase with finasteride does not adversely affect bone mineral density.

Original languageEnglish (US)
Pages (from-to)2105-2108
Number of pages4
JournalJournal of Urology
Volume167
Issue number5
DOIs
StatePublished - 2002

Keywords

  • Bone density
  • Finasteride
  • Prostatic hyperplasia
  • Stanolone

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'The long-term effect of specific type II 5α-reductase inhibition with finasteride on bone mineral density in men: Results of a 4-year placebo controlled trial'. Together they form a unique fingerprint.

Cite this